POCUS-Guided Esmolol in Septic Shock: A Pilot RCT

The goal of this pilot clinical trial is to determine if conducting a larger study using point-of-care ultrasound (POCUS) to guide beta-blocker therapy in patients with septic shock is feasible. Septic shock is a life-threatening condition where infection causes dangerously low blood pressure, requiring medications to support the heart and circulation. In septic shock, the body's stress response causes the heart to beat too fast, which can worsen organ damage. Beta-blockers are medications that slow the heart rate and may improve outcomes, but previous studies have shown mixed results. Some patients may be harmed by beta-blockers if they have not received enough fluids or if their heart is not functioning well. This study uses ultrasound to identify patients who are most likely to benefit and least likely to be harmed by beta-blocker therapy. The main questions this study aims to answer are: Is it feasible to recruit patients, obtain consent, perform ultrasound screening, and follow the study protocol? Researchers will compare two groups: one receiving the beta-blocker esmolol versus another receiving standard care, to assess the feasibility of a larger trial. Participants in the esmolol group will receive an intravenous infusion titrated to achieve a target heart rate of 75-95 beats per minute for up to 5 days or until shock resolves. All participants will be monitored for 90 days to track survival and organ function.

NCT Number	NCT07313605
Lead Sponsor	John Basmaji Collaborators: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, Western University, Canada
Conditions	Septic Shock
Enrollment	100 participants
Start Date	2026-01-15
Primary Completion	2028-01-15 (estimated)
Study Completion	2028-04-15 (estimated)
Updated on ClinicalTrials.gov	2026-01-06